'On consolidated basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Gland Pharma has increased 2.36% to Rs 1405.83 crore. Operating profit margin has declined from 23.60% to 21.13%, leading to 8.34% decline in operating profit to Rs 297.06 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 37.64% to 36.84%. Purchase of finished goods cost fell from 0.45% to 0.20%. Employee cost increased from 22.16% to 25.01%. Other expenses fell from 16.20% to 15.43%. Power and Oil fuel cost fell from 4.24% to 3.44%.
Other income rose 12.23% to Rs 59.66 crore. PBIDT fell 5.44% to Rs 356.72 crore. Provision for interest rose 0.99% to Rs 6.11 crore. Loan funds declined from Rs 357.03 crore as of 30 September 2023 to Rs 326.63 crore as of 30 Sept...
Pleaselogin & subscribe to view the full report.
More Reports
-
Stable performance on growth, asset quality and margins
-
Margins improve, VNB rises
-
Strong performance with improved combined ratio
-
Revenue up 29% YoY, Net Profit up 28.9% YoY in Q3FY2025
|
|